News
-
-
PRESS RELEASE
ENOGIA: ENOGIA secures €2 million in financing from Vatel Capital, which can be increased to €3 million - Transaction to support the Turbo 2028 plan
ENOGIA secures €2 million in financing from Vatel Capital, with potential increase to €3 million, to support the Turbo 2028 plan. Strong commercial performance confirmed by recent contracts, particularly in South Korea -
-
PRESS RELEASE
Aramis Group - Declaration of transactions on own shares conducted from Dec 15 to Dec 19, 2025
Aramis Group declares recent purchases of own shares (FR0014003U94) conducted from December 15 to December 19, 2025, in compliance with regulations. More details on the transactions available on their website -
PRESS RELEASE
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
AB Science's patent for masitinib in the treatment of sickle cell disease is formally granted in the United States, providing long-term protection until 2040. The biomarker Phase 2 in cooperation with AP-HP is fully funded -
-
-
-
REGULATED PRESS RELEASE
DISCLOSURE OF TRANSACTIONS IN OWN SHARES FROM DECEMBER 15 TO DECEMBER 19, 2025
-
PRESS RELEASE
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG corrects comprehensively revenues from bill-and-hold agreements
Gerresheimer AG corrects revenues from bill-and-hold agreements, impacting 2024 financial statements. Investigation shows early recognition not compliant with IFRS. Revenues corrected in 2025 statements
